Clinical Trials › NCT04466150
Active, Not RecruitingPhase 4
Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset
Sponsored by University of California, San Francisco
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 30
Target enrollment
1
U.S. states
Aug 2020
Start date
Jul 2027
Expected completion
Interventions / Treatments
Ocrelizumab
Conditions studied
Relapsing Multiple Sclerosis
Where this trial is running (1 site)
California1 site
San Francisco
Participating MS centers on MS Buddy (1)
UCSF Multiple Sclerosis Center
San Francisco, CA
San Francisco, CA
MS centers in California
Compare treatment centers near a trial site by center type, providers and trials.
View California centersMore Phase 4 trials
Browse all Phase 4 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.